Citrus tamurana
Citrus tamurana has been studied in 1 paper since 2024: 1 trial in people. The newest paper, Oct 17, 2024: “Citrus tamurana Hort. ex Tanaka (Hyuganatsu orange)-derived arabinogalactan suppresses bone turnover in postmenopausal women: A randomized placebo-controlled study”.
1 paper studies it2 findingsUpdated
See all 1 papers on citrus tamurana
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“the study group had significantly lower TRACP5b and P1NP levels at day 90 than the control group (mean [95% confidence interval]; TRACP5b: 310.0 [269.2-350.9] vs. 386.4 [341.2-431.6] mU/dL”
None of its findings points the other way.
- 1 lab in 1 country
- Human trial1
Studies in people
1 study gave citrus tamurana to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases TRACP-5b310.0 [269.2-350.9] vs. 386.4 [341.2-431.6] mU/dL down: Decreases P1NP53.7 [48.6-58.7] vs. 70.3 [64.1-76.4] ng/mL | Randomized trial90 days | 63 peopleWomenOlder adults; Postmenopausal women; postmenopausal women | The journal of obstetrics and gynaecology research, Oct 17, 2024 |
What did studies of citrus tamurana find?
2Studies of citrus tamurana measured 2 outcomes: P1NP and TRACP-5b.
P1NP
downin humans1
1 study
P1NP
downin humans1
Citrus tamurana decreases P1NP in humans (postmenopausal women) (53.7 [48.6-58.7] vs. 70.3 [64.1-76.4] ng/mL).
Human trialpostmenopausal womenarabinogalactan-rich juiceblood90 daysfemalesn = 63
TRACP-5b
downin humans1
1 study
TRACP-5b
downin humans1
Citrus tamurana decreases TRACP-5b in humans (postmenopausal women) (310.0 [269.2-350.9] vs. 386.4 [341.2-431.6] mU/dL).
Human trialpostmenopausal womenarabinogalactan-rich juiceblood90 daysfemalesn = 63